Epigallocatechin-3-gallate (EGCG) ( DrugBank: Epigallocatechin, EGCG )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
28 | 全身性アミロイドーシス | 1 |
85 | 特発性間質性肺炎 | 2 |
28. 全身性アミロイドーシス
臨床試験数 : 261 / 薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02015312 (ClinicalTrials.gov) | April 2013 | 18/11/2013 | A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) | A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) | Light Chain (AL) Amyloidosis;Cardiac Involvement | Drug: Epigallocatechin-3-gallate (EGCG);Drug: Placebo | Florian Michel | German Federal Ministry of Education and Research | Completed | 18 Years | N/A | All | 38 | Phase 2 | Germany |
85. 特発性間質性肺炎
臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05195918 (ClinicalTrials.gov) | April 1, 2022 | 2/12/2021 | Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients | Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect | Idiopathic Pulmonary Fibrosis | Combination Product: EGCG + Nintedanib;Combination Product: EGCG + Pirfenidone;Combination Product: Placebo + Nintedanib or Pirfenidone | Hal Chapman | University of Michigan;Cornell University;Massachusetts General Hospital;Temple University | Not yet recruiting | 40 Years | 85 Years | All | 50 | Phase 1 | United States |
2 | NCT03928847 (ClinicalTrials.gov) | July 1, 2018 | 18/4/2019 | Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. | Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. | Idiopathic Pulmonary Fibrosis | Drug: Epigallocatechin-3-gallate (EGCG) | University of California, San Francisco | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 40 Years | 70 Years | All | 35 | Early Phase 1 | United States |